The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases
出版年份 2023 全文链接
标题
The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases
作者
关键词
-
出版物
PHARMACOLOGY & THERAPEUTICS
Volume 245, Issue -, Pages 108399
出版商
Elsevier BV
发表日期
2023-03-30
DOI
10.1016/j.pharmthera.2023.108399
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- P. gingivalis infection upregulates PD-L1 expression on dendritic cells, suppresses CD8+ T cell responses, and aggravates oral cancer
- (2023) Junling Ren et al. Cancer Immunology Research
- Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study
- (2022) Maximilian J. Mair et al. EUROPEAN JOURNAL OF CANCER
- Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy
- (2022) Kentaro Ohuchi et al. JOURNAL OF DERMATOLOGY
- Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
- (2022) Annika Fendler et al. LANCET
- SARS-CoV-2 Induces Cytokine Responses in Human Basophils
- (2022) Srinivasa Reddy Bonam et al. Frontiers in Immunology
- SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents
- (2022) Charlotte Fenioux et al. JAMA Oncology
- Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer
- (2022) Annika Fendler et al. CANCER CELL
- Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
- (2022) Paula Dobosz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
- (2022) Sjoukje F Oosting et al. LANCET ONCOLOGY
- PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration
- (2022) Wenji Piao et al. Nature Communications
- IFN-γ Induces PD-L1 Expression in Primed Human Basophils
- (2022) Srinivasa Reddy Bonam et al. Cells
- Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
- (2022) Patricia Iranzo et al. Frontiers in Medicine
- Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report
- (2022) Angioletta Lasagna et al. Immunotherapy
- PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
- (2022) Ramin Sedaghat Herati et al. NATURE IMMUNOLOGY
- PD-L1 Up-Regulation in Prostate Cancer Cells by Porphyromonas gingivalis
- (2022) Sabine Groeger et al. Frontiers in Cellular and Infection Microbiology
- Modulation of viral replication, apoptosis and antiviral response by induction and mutual regulation of EGR and AP-1 family genes during coronavirus infection
- (2022) Lixia Yuan et al. Emerging Microbes & Infections
- SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
- (2022) Evangelos Terpos et al. Cancers
- Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
- (2022) Maria A. Lopez-Olivo et al. Vaccines
- Role of the PD-1 and PD-L1 axis in COVID-19
- (2022) Srinivasa R Bonam et al. Future Microbiology
- An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery
- (2022) Jiao Shen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
- (2022) Masao Hashimoto et al. NATURE
- Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities
- (2022) Konstantinos Tsiakos et al. Vaccines
- Addressing resistance to immune checkpoint inhibitor therapy – an urgent unmet need
- (2021) Siwen Hu-Lieskovan et al. Future Oncology
- Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody
- (2021) Shiwen Peng et al. mBio
- PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques
- (2021) Keith D. Kauffman et al. Science Immunology
- SARS-CoV-2 vaccination and phase 1 cancer clinical trials
- (2021) Timothy A Yap et al. LANCET ONCOLOGY
- COVID-19 vaccination: the VOICE for patients with cancer
- (2021) Astrid A. M. van der Veldt et al. NATURE MEDICINE
- A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells
- (2021) Torben Knuschke et al. mBio
- Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
- (2021) R. Palich et al. ANNALS OF ONCOLOGY
- 522 Associations between influenza vaccine and immunotherapy outcomes in metastatic melanoma patients
- (2021) M. Erickson et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis
- (2021) Waleed Kian et al. ANTI-CANCER DRUGS
- Seroconversion rates following COVID-19 vaccination among patients with cancer
- (2021) Astha Thakkar et al. CANCER CELL
- Severe cutaneous adverse reaction following COVID‐19 vaccination and immunotherapy: a second hit?
- (2021) K. Hussain et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- COVID-19 vaccines in adult cancer patients with solid tumors undergoing active treatment: seropositivity and safety. A prospective observational study in Italy
- (2021) Luigi Cavanna et al. EUROPEAN JOURNAL OF CANCER
- High levels of anti–SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine
- (2021) Dominic Fong et al. EUROPEAN JOURNAL OF CANCER
- Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
- (2021) Cengiz Karacin et al. Future Oncology
- Effect of influenza vaccination on immune-related adverse events in patients receiving single-agent immune checkpoint inhibitors for the treatment of cancer.
- (2021) Naga Malleswari Vutukuri et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2
- (2021) Lewis Au et al. NATURE MEDICINE
- CD8+ T Cell Exhaustion in Cancer
- (2021) Joseph S. Dolina et al. Frontiers in Immunology
- Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
- (2021) Amir Massarweh et al. JAMA Oncology
- Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
- (2021) Tal Goshen-Lago et al. JAMA Oncology
- Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin
- (2021) Erkko Ylösmäki et al. Journal for ImmunoTherapy of Cancer
- PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8 + T cells in lymphoid tissue
- (2021) Sheikh Abdul Rahman et al. Science Immunology
- High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
- (2021) R. Palich et al. ANNALS OF ONCOLOGY
- Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection
- (2021) Annoor Awadasseid et al. BIOMEDICINE & PHARMACOTHERAPY
- COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer
- (2021) Cong Zeng et al. CANCER CELL
- Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer
- (2021) Annika Fendler et al. CANCER CELL
- Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer
- (2021) Jane C. Figueiredo et al. CANCER RESEARCH
- Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution
- (2021) Vincenzo Di Noia et al. CLINICAL CANCER RESEARCH
- Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses
- (2021) Valérie Gounant et al. Journal of Thoracic Oncology
- mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
- (2021) Sjoukje F Oosting et al. LANCET ONCOLOGY
- Wnt-β-Catenin Signaling in Human Dendritic Cells Mediates Regulatory T-Cell Responses to Fungi via the PD-L1 Pathway
- (2021) Anupama Karnam et al. mBio
- Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations
- (2021) Maximilian J. Mair et al. JAMA Oncology
- The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells
- (2021) Stephanie Laba et al. SEMINARS IN CANCER BIOLOGY
- Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1
- (2020) A. Bayle et al. ANNALS OF ONCOLOGY
- Cell-Mediated Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors
- (2020) Chang Kyung Kang et al. JOURNAL OF INFECTIOUS DISEASES
- The Role of PD-1 in Acute and Chronic Infection
- (2020) Jil M. Jubel et al. Frontiers in Immunology
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
- (2020) Jin-Yu Sun et al. Biomarker Research
- Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices
- (2019) Scott D. Ramsey et al. JAMA Oncology
- PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy
- (2019) Arash Salmaninejad et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors (ICI)
- (2019) Curtis R Chong et al. CLINICAL INFECTIOUS DISEASES
- Immune related adverse events in NSCLC patients treated with immune checkpoint therapy who received the influenza vaccination versus no vaccination.
- (2019) Haritha G. Reddy et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restore the Function of Anti-Viral Tissue-Resident CD8+ TRM Cells and Reduce Ocular Herpes Simplex Infection and Disease in HLA Transgenic Rabbits
- (2019) Soumyabrata Roy et al. JOURNAL OF VIROLOGY
- TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
- (2019) Omar Khan et al. NATURE
- AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
- (2019) Vasileios Atsaves et al. Cancers
- Tfh cell response in influenza vaccines in humans: what is visible and what is invisible
- (2019) Hideki Ueno CURRENT OPINION IN IMMUNOLOGY
- Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors
- (2019) Morgan E Gwynn et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor
- (2019) Bhumsuk Keam et al. CLINICAL INFECTIOUS DISEASES
- OA01.04 Safety and Efficacy of Flu Vaccination After Treatment with Immune Checkpoint Inhibitors: a Retrospective Review
- (2019) N. Roberts et al. Journal of Thoracic Oncology
- PD-1 of Sigmodon hispidus: Gene identification, characterization and preliminary evaluation of expression in inactivated RSV vaccine-induced enhanced respiratory disease
- (2019) Abenaya Muralidharan et al. Scientific Reports
- Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer
- (2019) Jenna H. Newman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
- (2018) Masao Hashimoto et al. Annual Review of Medicine
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- T Follicular Helper Cells in Autoimmune Disorders
- (2018) Noémie Gensous et al. Frontiers in Immunology
- Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events
- (2018) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Safety of influenza vaccination in patients undergoing immunotherapy treatment for advanced cancer.
- (2018) Curtis Robert Chong et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI).
- (2018) Ragisha Gopalakrishnan et al. JOURNAL OF CLINICAL ONCOLOGY
- Influenza vaccination in patients with lung cancer receiving anti–programmed death receptor 1 immunotherapy does not induce immune-related adverse events
- (2018) Dirk H. Wijn et al. EUROPEAN JOURNAL OF CANCER
- INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study
- (2018) Melissa Bersanelli et al. Immunotherapy
- Immune Protection of SIV Challenge by PD-1 Blockade During Vaccination in Rhesus Monkeys
- (2018) Enxiang Pan et al. Frontiers in Immunology
- IVIG-mediated effector functions in autoimmune and inflammatory diseases
- (2017) Caroline Galeotti et al. INTERNATIONAL IMMUNOLOGY
- Aspergillus fumigatus Cell Wall α-(1,3)-Glucan Stimulates Regulatory T-Cell Polarization by Inducing PD-L1 Expression on Human Dendritic Cells
- (2017) Emmanuel Stephen-Victor et al. JOURNAL OF INFECTIOUS DISEASES
- Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
- (2017) Peng-Fei Wang et al. Frontiers in Pharmacology
- Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model
- (2016) Lydia Dyck et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
- (2016) Andrea Schietinger et al. IMMUNITY
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death
- (2016) Frederick J. Kohlhapp et al. Cell Reports
- Translational Implications of Tumor Heterogeneity
- (2015) M. Jamal-Hanjani et al. CLINICAL CANCER RESEARCH
- PD-1 Deficiency Enhances Humoral Immunity of Malaria Infection Treatment Vaccine
- (2015) Taiping Liu et al. INFECTION AND IMMUNITY
- PD-1 Suppresses Protective Immunity toStreptococcus pneumoniaethrough a B Cell–Intrinsic Mechanism
- (2015) Jerome T. McKay et al. JOURNAL OF IMMUNOLOGY
- Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer
- (2015) Yaxiong Zhang et al. MEDICINE
- Practical review of immunizations in adult patients with cancer
- (2015) Ella J Ariza-Heredia et al. Human Vaccines & Immunotherapeutics
- Transcription factor complex AP-1 mediates inflammation initiated byChlamydia pneumoniaeinfection
- (2012) Anyou Wang et al. CELLULAR MICROBIOLOGY
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1/PD-L1 Blockade Can Enhance HIV-1 Gag-specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines
- (2012) Bingbing Dai et al. MOLECULAR THERAPY
- Programmed Death 1 and Cytokine Inducible SH2-Containing Protein Dependent Expansion of Regulatory T Cells Upon Stimulation With Mycobacterium tuberculosis
- (2011) Sivakumar Periasamy et al. JOURNAL OF INFECTIOUS DISEASES
- Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF
- (2010) Michael Quigley et al. NATURE MEDICINE
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search